Olin Corporation OLN
Composite 29/100; the shares have moved about 53% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 16/100 — a strong mark against it.
Valuation ranks 58/100 — a slight point in its favour. Income ranks 54/100 — a slight point in its favour.
Quality ranks 16/100 — a strong mark against it. Momentum ranks 16/100 — a strong mark against it. Growth ranks 19/100 — a strong mark against it.
What the company does Olin Corporation operates three chemical segments—Chlor Alkali Products and Vinyls, Epoxy, and Winchester—and produces chlorine, caustic soda, epoxy resins, and ammunition. Its Chlor Alkali and Epoxy units serve industrial end-markets, while Winchester focuses on sporting and military ammunition.
Key financials Olin’s profitability metrics are weak: ROE -9.8%, ROA 0.1%, and net margin -2.8%. Revenue fell -3.7% and EPS dropped -97.5%. Leverage is high (Debt/Equity 1.99, Net debt/EBITDA 6.03), and interest coverage is negative (-0.06).
Stock health The stock shows poor quality scores (Overall 31.7) with low momentum (Momentum 30.2) and high valuation percentile (62.0). Recent 3-month performance is -18.45%, though 12-month is +4.71%.
Price vs fair value The stock trades at a PREMIUM of 64.90% versus our fair-value estimate and a discount of 17.92% to the analyst 12-month target. - Q2 2026 earnings matched estimates, suggesting stability but not growth (Zacks, 2026-07-30). - Forward P/E of 42.73 reflects high expectations despite weak margins (Valuation data). - Dividend yield 3.4% with payout 173.9% signals unsustainable distribution (Key Financials). - Analyst count of 14.0 supports the target discount (Analyst View).
Looking forward Outlook hinges on margin recovery in Chlor Alkali and Epoxy segments and ammunition demand stability. Analysts see upside to $26.14, but current premium to fair value suggests limited near-term upside without execution improvement.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.